R 969.4；R 573.1
〔摘 要〕 目的：分析消化性溃疡患者采用奥美拉唑肠溶胶囊与康复新液联合治疗的临床效果。 方法：选取 2020 年 3 月 至 2022 年 7 月平顶山市妇幼保健院收治的 84 例消化性溃疡患者作为研究对象，随机分为对照组和观察组，各 42 例。对照 组单用奥美拉唑肠溶胶囊治疗，观察组采用奥美拉唑肠溶胶囊联合康复新液治疗。比较两组患者临床指标改善情况、临床 症状改善时间、临床疗效、不良反应发生情况。 结果：治疗后，两组患者各项临床指标均低于治疗前，且观察组低于对照组， 差异具有统计学意义（P ＜ 0.05）。观察组患者各项临床症状改善时间均短于对照组，差异具有统计学意义（P ＜ 0.05）。 观察组患者临床疗效率高于对照组，差异具有统计学意义（P ＜ 0.05）。两组患者不良反应发生率比较，差异无统计学意义 （P ＞ 0.05）。 结论：应用奥美拉唑肠溶胶囊联合康复新液治疗消化性溃疡患者，可以使其各项临床指标显著改善，缩短 症状缓解时间，提升临床疗效，且联合用药不会增加不良反应发生，具有安全性。
〔Abstract〕 Objective To analyze the clinical effect of omeprazole enteric-coated capsule combined with Kangfuxin liquid in the treatment of patients with peptic ulcer. Methods A total of 84 patients with peptic ulcer admitted to Pingdingshan Maternal and Child Health Hospital from March 2020 to July 2022 were selected as the study objects and randomly divided into a control group and an observation group, with 42 cases in each group. The control group was treated with omeprazole enteric capsule alone, and the observation group was treated with omeprazole enteric-capsule combined with Kangfuxin solution. Clinical indicators, improvement time of clinical symptoms, clinical efficacy and occurrence of adverse reactions were compared between the two groups. Results After treatment, all clinical indexes in the two groups were lower than those before treatment, the clinical indexes in the observation group were lower than those in the control group, the differences were statistically significant (P < 0.05). The improvement time of clinical symptoms in the observation group were shorter than those in the control group, and the differences were statistically significant (P < 0.05). The clinical efficacy rate of the observation group was higher than that of the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion The application of omeprazole enteric-coated capsule combined with Kangfuxin liquid in the treatment of patients with peptic ulcer can significantly improve various clinical indicators, shorten the time of symptom relief, and enhance clinical efficacy, and the combination of medication will not increase the occurrence of adverse reactions, and has safety.